Four EGFR-Mutated Lung Cancers That Changed Form After Osimertinib
This lung cancer diagnosis at a glance
- Subtype
- Small Cell Lung Cancer
- Biomarkers
- EGFR exon 19 deletion; TP53 p.D259V
- Sex
- female
- Treatment
- targeted therapy, chemotherapy and radiation
- Outcome
- In Memory
Treatment course, step by step
- She received osimertinib for about 25 months.
- After transformation to small cell lung cancer, she received carboplatin and etoposide with radiation to a mediastinal lesion.
- After progression 14 months later, she switched to topotecan for another 13 months.
What happened, in summary
A 58-year-old woman with EGFR-mutated lung cancer received osimertinib for about 25 months. When the cancer progressed, a new biopsy showed that the tumor had changed into small cell lung cancer. The transformed tumor retained the EGFR exon 19 deletion that had been present earlier and also carried a TP53 p.D259V alteration. She then received carboplatin and etoposide chemotherapy together with radiation directed at a mediastinal lesion. The cancer remained controlled for a period, but progression was documented 14 months later. She then changed to topotecan chemotherapy and continued it for another 13 months. The disease ultimately progressed again, and she died 2 months later. Her course illustrates a major change in tumor biology during targeted treatment, requiring a shift from osimertinib to treatment used for the transformed small cell cancer.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- EGFR Mutation Lung Cancer 112 stories
- Carboplatin for Lung Cancer 168 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer